HPTN 083‐02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study

• Published in: Journal of the International AIDS Society Vol. 27; no. 5; pp. e26252 - n/a
• Main Authors: Psaros, Christina, Goodman, Georgia R., Lee, Jasper S., Rice, Whitney, Kelley, Colleen F., Oyedele, Temitope, Coelho, Lara E., Phanuphak, Nittaya, Singh, Yashna, Middelkoop, Keren, Griffith, Sam, McCauley, Marybeth, Rooney, James, Rinehart, Alex R., Clark, Jesse, Go, Vivian, Sugarman, Jeremy, Fields, Sheldon D., Adeyeye, Adeola, Grinsztejn, Beatriz, Landovitz, Raphael J., Safren, Steven A.
• Format: Journal Article
• Language: English
• Published: Switzerland John Wiley & Sons, Inc 01.05.2024; Wiley
• Subjects: Adult; Analysis; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - therapeutic use; Biological products industry; Brazil; Cisgender; Demographics; Diketopiperazines; Disease prevention; Education; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - administration & dosage; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - therapeutic use; Ethnicity; Female; Gender identity; Hispanic Americans; HIV; HIV Infections - drug therapy; HIV Infections - prevention & control; HIV prevention; Homosexuality, Male; Human immunodeficiency virus; Humans; injectable PrEP; Injection; Injections; Interviews; Interviews as Topic; Male; Marital status; Medication Adherence - statistics & numerical data; men who have sex with men; Middle Aged; Pre-Exposure Prophylaxis - methods; Prevention; pre‐exposure prophylaxis; Prophylaxis; Pyridines - administration & dosage; Pyridines - therapeutic use; Pyridones - administration & dosage; Pyridones - therapeutic use; qualitative; Sexually transmitted diseases; Sociodemographics; STD; Tenofovir - administration & dosage; Tenofovir - therapeutic use; Transgender people; Transgender persons; Transgender Persons - psychology; transgender women; Young Adult; Brazil; South Africa; United States; Illinois; Atlanta Georgia; Rio de Janeiro Brazil; Chicago Illinois; United States > US; pre‐exposure prophylaxis; HIV prevention; qualitative; injectable PrEP; men who have sex with men; transgender women

Introduction HPTN 083 demonstrated the superiority of long‐acting cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre‐exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first op...